retatrutide news Vial of unapproved peptide had double the strength indicated on label Retatrutide Achieves Large Weight Decreases

Compared to the corresponding endogenous hormones, retatrutide is more potent at GIPR by a factor of 8.9, and less potent at GCGR and GLP-1R by factors of 0.3 and 0.4, respectively 7 (Fig

H.DeaconC

In addition, the limitations of GLP-1R agonist therapy, which may cause gastrointestinal adverse effects and significantly alter the patients physiological state, make it not widely applicable to all patients

Novo Nordisk filed the New Drug Application (NDA) for CagriSema in early 2026, based on positive results from the REDEFINE phase 3 trial program

Semaglutide is a medication known as a GLP-1 receptor agonist

The additive cardiovascular strain from both medications could precipitate another event in someone whose cardiovascular system has already demonstrated vulnerability